ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

News

ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress

  • Data presented during the late-breaker oral presentation of the TREK-AD study demonstrate eblasakimab’s potential as the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation
  • New data from a post-hoc analysis of patients with severe disease (baseline EASI score at least 21), representing 63% of ITT patients, show monthly dosing with 600 mg eblasakimab for 16 weeks led to a 74.5% reduction in EASI score (versus 38.0% on placebo, p<0.0001) and EASI-75 of 53.6% (versus 12.9% on placebo, p=0.0009), representing a marked widening in placebo-adjusted efficacy

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the late-breaking oral presentation of data from the Phase 2b TREK-AD study of eblasakimab in adults with moderate-to-severe atopic dermatitis (AD) at the 32nd European Academy of Dermatology and Venereology (EADV) Congress. For more information, please refer to the press release.